Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

(2011) L. Alinari et al.   BLOOD

The future of anti-CD20 monoclonal antibodies: are we making progress?

(2011) W. Alduaij et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

(2011) G. Cartron et al.   CLINICAL CANCER RESEARCH

CD40 stimulation sensitizes CLL cells to rituximab-induced cell death

(2011) M Jak et al.   LEUKEMIA

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis

(2008) A. Ivanov et al.   CLINICAL CANCER RESEARCH

Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease

(2008) Heng Du et al.   NATURE MEDICINE